NDAINJECTIONINJECTABLE
Approved
May 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
OPTIRAY 320 (ioversol) by Guerbet is x-ray contrast activity [moa]. First approved in 1998.
Drug data last refreshed 11h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OPTIRAY 320 is an injectable radiographic contrast agent containing ioversol, a non-ionic iodinated compound used to enhance X-ray imaging in diagnostic procedures. It works by increasing radiodensity in targeted anatomical regions, improving visualization of blood vessels, organs, and tissues during angiography and other radiological examinations. The product serves as a standard-of-care contrast medium in interventional radiology and diagnostic imaging.
LOE Approaching
As a legacy product approaching loss of exclusivity with moderate competitive pressure (30%), the brand team is likely focused on market defense and cost management rather than expansion.
Mechanism of Action
X-Ray Contrast Activity
Pharmacologic Class:
Radiographic Contrast Agent
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on OPTIRAY 320 offers limited growth opportunities given its LOE-approaching status, but provides valuable experience in mature product management, competitive defense, and operational excellence in a heavily commoditized market. This role is best suited for professionals seeking stability, cost-management expertise, and hands-on market defense rather than high-growth trajectory or innovation-focused career development.
Brand Manager
Worked on OPTIRAY 320 at Guerbet? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.